The management of extremity soft tissue sarcoma is shifting towards a patient-tailored approach utilizing prognostic tools and gene expression profiles.
PASTA multimodality approach is often used in the management of high-grade soft tissue sarcoma of the extremity (eSTS).Limb-sparing surgery is the keystone of eSTS management, often accompanied with radiotherapy (RTX) and/or chemotherapy (CTX).The National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guideline recommend RTX and CTX in selected groups of high-risk patients. 1,2However, the identification of these high-risk patients who benefit from perioperative treatment remains challenging.In the last decade, several prognostic tools and prognostic gene expression profiles have been developed to facilitate clinical decision-making for the indication of multimodality therapy.This marks a shift from a one-size-fits-all approach to a patient-tailored approach for the management and surveillance of eSTS.
No takes yet. Share an insight, caveat, or question.
Acem et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: